Publication:
The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria

Simple item page
dc.contributor.authorSALMAN, ANDAÇ
dc.contributor.authorsSalman, Andac; Comert, Elif
dc.date.accessioned2022-03-12T22:29:47Z
dc.date.available2022-03-12T22:29:47Z
dc.date.issued2019
dc.description.abstractBackground: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to investigate the effectiveness and safety of omalizumab 450 mg in CSU. Methods: A retrospective cohort study was conducted. The response to therapy was evaluated using the Urticaria Activity Score over 7 days (UAS7) and the Urticaria Control Test (UCT). Patients showing complete response (CR) (UAS7: 0-1) to omalizumab 300 mg (Group 1) and patients receiving at least 3 doses of omalizumab 450 mg (Group 2) between 2016 and 2018 were included. Results: A total of 72 patients (Group 1: 59; Group 2: 13) were included. In Group 2, the mean UAS7 score decreased from 18.6 to 5.1 and the mean UCT score increased from 8.6 to 12 after a mean 4.3 courses of 450 mg omalizumab treatment. Of the 13 patients in Group 2, 6 had CR and 3 had good disease control (UAS7: 2-6). The rate of patients with low baseline IgE levels (< 43 IU/mL) was significantly higher in Group 2. Conclusions: Higher doses of omalizumab are effective and safe in patients with CSU that is unresponsive to omalizumab 300 mg. Lower baseline total IgE levels might be used as a predictor of nonresponse to omalizumab and the need for higher doses.
dc.identifier.doi10.1177/1203475419847956
dc.identifier.eissn1615-7109
dc.identifier.issn1203-4754
dc.identifier.pubmed31030540
dc.identifier.urihttps://hdl.handle.net/11424/235411
dc.identifier.wosWOS:000484514600004
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS INC
dc.relation.ispartofJOURNAL OF CUTANEOUS MEDICINE AND SURGERY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectchronic spontaneous urticaria
dc.subjectomalizumab
dc.subjectupdosing
dc.subjectMINIMAL IMPORTANT DIFFERENCE
dc.subjectDISEASE-ACTIVITY
dc.subjectIGE LEVELS
dc.subjectMANAGEMENT
dc.subjectDIAGNOSIS
dc.subjectGUIDELINE
dc.titleThe Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria
dc.typearticle
dspace.entity.typePublication
local.avesis.id165b96af-dcb1-4745-846a-68b523bd2553
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
local.journal.quartileQ3
oaire.citation.endPage500
oaire.citation.issue5
oaire.citation.startPage496
oaire.citation.titleJOURNAL OF CUTANEOUS MEDICINE AND SURGERY
oaire.citation.volume23
relation.isAuthorOfPublication22ba329a-4b06-4eb1-8549-b8b32f2d766b
relation.isAuthorOfPublication.latestForDiscovery22ba329a-4b06-4eb1-8549-b8b32f2d766b

Files

Collections

Research Outputs